New Combined Therapy Helps Extend Lives of Men With Prostate Cancer

Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. The findings were published in the peer-reviewed journal The Lancet.

Researchers uncover how tumors circumvent prostate cancer therapy, identify promising treatment strategy

A Cleveland Clinic-led research team uncovered how tumors circumvent prostate cancer therapy and identified a promising new strategy for treatment. Findings were published in Proceedings of the National Academy of Sciences (PNAS). Antiandrogen strategies remain the backbone for advanced prostate…

TipSheet: Research Highlights Potential Benefits of Vibrators on Women’s Pelvic Health

Cedars-Sinai urology experts will present their latest advances in urologic medicine at the annual scientific meeting of the American Urological Association (AUA) in New Orleans May 13-16, 2022. Among over 2,200 abstracts, one by Alexandra Dubinskaya, MD, a female pelvic medicine and reconstructive surgery (FPMRS) specialist—Is It Time for FPMRS to Prescribe Vibrators?—was selected to be included in the 117th AUA press session on May 13, 2022, at 9 a.m. CT.

Henry Ford Health First in Michigan to Offer Robotic High-Intensity Focused Ultrasound for Prostate Cancer

Henry Ford Health is the first in Michigan to offer Robotic High Intensity Focused Ultrasound (HIFU) for the treatment of localized prostate cancer. This non-surgical treatment option spares surrounding healthy tissue, while allowing for a quicker treatment time and recovery for the patient.

April Research Highlights

This tipsheet highlights the latest medical discoveries and faculty news at Cedars-Sinai. Links to full news releases are included with each item.

Yale Cancer Center Study Shows Rates of PSA Testing for Prostate Cancer Increased After Revised National Guidelines

In a large study led by Yale Cancer Center, more men received a prostate-specific antigen or PSA test to detect prostate cancer following revisions to the recommendation by the U.S. Preventative Services Task Force on screening. The results also showed significant increases in PSA testing among older men, a group for whom screening is not routinely recommended.

Studies Find B7-H3 Protein a Novel, Promising Target for Prostate Cancer Treatments

The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center. The studies were presented recently at the European Society for Medical Oncology (ESMO) 2021 Conference.

Genetic biomarker test predicts recurrence and survival outcomes for men with high-risk prostate cancer

A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study, which examined biopsy samples collected from three large, randomized clinical trials, indicates that physicians potentially can use genetic test scores to personalize treatment for men with the most aggressive form of prostate cancer. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Shortened course of radiation therapy offers similar long-term side effects following prostate removal surgery

Using fewer—but higher—doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a new, multi-institutional clinical trial shows.

New Noninvasive Tests for Colon and Prostate Cancer Presented at the 2021 AACC Annual Scientific Meeting

Two research teams have developed new noninvasive tests that use either blood or saliva samples to diagnose cases of colorectal cancer or prostate cancer, respectively. Presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, these tests could facilitate screening efforts for colorectal cancer and allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.

Active surveillance for low-risk prostate cancer: New data on risk factors for switching to active treatment

For men with “low-risk” prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Advancements in Prostate Cancer Treatments are Providing Better Outcomes for Men

Over the last decade, advancements have been made in the diagnosis and treatment of prostate cancer that are saving more lives. Tina Mayer, MD, a medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey shares some insight.

Mount Sinai researchers develop novel therapy that could be effective in many cancers

New York, NY (July 23, 2021) — Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery , a…

Bidirectional impact of cardiovascular disease, cancer in Blacks focus of new AHA center

Cardiovascular disease and cancer, the nation’s top two killers, share common ground like obesity and chronic inflammation, as well as a disproportionate impact on Black Americans. A new American Heart Association-funded center at the Medical College of Georgia is working…

Mount Sinai Welcomes Robotic Prostate Surgery Pioneer Mani Menon, MD

Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System. He will also serve as a Professor of Urology, Director of Education and Director of the Precision Prostatectomy Program in the Department of Urology at Icahn Mount Sinai and Center of Excellence for Prostate Cancer at The Tisch Cancer Institute.

Study Sheds Light on Persistent Racial Disparities in Prostate Cancer Care in the United States

Black men most likely to benefit from advanced prostate cancer therapies are 11 percent less likely to get them than non-Black men. This happens despite apparent equal opportunities in obtaining health care services, a new study in American veterans shows.

BET inhibitors show promise in overcoming lineage plasticity, a newly recognized form of resistance to prostate cancer drugs

In a new study, a team of researchers uncovered new mechanisms underlying an important type of resistance to modern prostate cancer drugs called lineage plasticity, where castration-resistant prostate cancers undergo a deadly identity switch. They also outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors.